|Bid||11.63 x 38500|
|Ask||11.64 x 45100|
|Day's Range||11.62 - 11.79|
|52 Week Range||7.48 - 13.49|
|Beta (5Y Monthly)||1.27|
|PE Ratio (TTM)||9.19|
|Forward Dividend & Yield||0.36 (3.10%)|
|Ex-Dividend Date||May 06, 2020|
|1y Target Est||13.95|
UBS has settled a lawsuit with a former junior trader who accused the Swiss bank of mishandling a complaint of rape and sexual assault by senior colleagues against her, representatives for the former employee said on Friday. "UBS and Ms A have reached a mutual resolution in relation to this matter as a result of which Ms A has withdrawn her claim," legal representatives for the claimant at Farore Law said. The claimant, who cannot be named for legal reasons, alleged that she faced gender discrimination and sexual harassment while working at the bank in London, and filed a claim in Britain for damages against the Swiss lender.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
(Bloomberg) -- UBS Group AG settled a lawsuit brought by a former trainee in London who said she was raped by a senior employee, according to her attorney.The Swiss lender agreed to settle the claim after the trainee, who was identified in court documents as Ms. A, alleged that UBS failed to protect her and that its investigation of her complaint was flawed. The female graduate, who worked on the trading floor, had also told former UBS investment-banking head Andrea Orcel of the “sexualized atmosphere” on the desk.“UBS and Ms. A have reached a mutual resolution in relation to this matter as a result of which Ms. A has withdrawn her claim,” her lawyer, Suzanne McKie, said in a statement.A representative for the bank declined to immediately comment. UBS said in a statement when the trainee brought her claim last year that it had conducted an independent investigation into sexual misconduct allegations and concluded that it had made no fundamental errors, but had recommended some changes. Terms of the settlement weren’t disclosed.The agreement comes as sexual harassment and discrimination comes under greater scrutiny in the wake of the MeToo movement and U.K. regulators step up efforts to hold financial firms and managers accountable.The trainee says she was compelled to sit near the employee whom she had accused of rape. The trainee had to take the fire escapes to avoid coming across the senior banker and raised this with the lender’s human-resources department, McKie said in a statement when she first brought her claim at the employment tribunal in March last year.The alleged rape was said to have taken place in September 2017 and is still being investigated by police.The alleged perpetrator resigned from the investment bank in March 2018, five months after he was suspended, two people familiar with the matter have previously said. UBS hadn’t started a formal disciplinary procedure by the time he departed the Swiss lender, the people said. The trainee, who can’t be identified for legal reasons, left the bank in June 2018.(Updates with scrutiny from regulators in sixth paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]
UBS announced today that Gail Konstantin, a Senior Vice President and Financial Advisor in the Firm’s White Plains, NY Office, has been named to Forbes/SHOOK list of Top Women Wealth Advisors for 2020.
UBS announced today that two Financial Advisors in the Wayzata office, Becky Falk and Kelli Puhl of the Falk, Puhl & Guillaume Wealth Management Team, have been named to the Forbes/SHOOK list of Top Women Wealth Advisors for 2020. Within the list of 1,000 women, Becky achieved a ranking of 188 placing her in the top 20% of women advisors achieving this recognition.
UBS Wealth Management USA is pleased to announce that it will expand its offering of Separately Managed Accounts (SMA) with no additional investment manager fee to third party asset managers. Starting July 7, clients will have access to nine additional strategies in this innovative pricing model, including Natixis Investment Managers/AIA, Breckinridge Capital Advisors and Goldman Sachs Asset Management, across equity and fixed income asset classes. In August, another nine strategies are expected to join from Franklin Templeton, Invesco, Brandes Investment Partners and PIMCO. All SMA strategies will be made available via WM USA's ACCESS, Strategic Wealth Portfolio (SWP) and/or the recently launched Advisor allocation Program (AAP) platforms.
UBS Investment Bank today announced that the ETRACS Midstream Energy Index ETN (NYSE Arca®: AMNA) began trading on NYSE Arca®. AMNA is linked to the Alerian Midstream Energy Index (Bloomberg: "AMNA Index").
A significant proportion of UBS's staff could continue to work from home even after the coronavirus crisis has ended, the bank's Chief Operating Officer Sabine Keller-Busse said on Monday. "It is conceivable that in the future up to a third of the staff will work remotely on a rotating basis," a UBS spokeswoman said. The changes will be implemented globally, although the exact number of UBS's 70,000 staff has not yet been determined.
KlaymanToskes, www.klaymantoskes.com, continues to investigate and pursue claims to recover investment losses suffered by investors in UBS’s (NYSE:UBS) Yield Enhancement Strategy ("YES"). KT believes that investor claims are meritorious as they relate to the marketing, offer, and sale of the YES strategy, including the sales presentation that was provided to customers.
Piraeus Bank <BOPr.AT> has hired JPMorgan and UBS to sell two portfolios of soured loans worth about 7 billion euros as it scrambles to clean up its balance sheet and tackle a new debt crisis triggered by the novel coronavirus, sources told Reuters. Piraeus, Greece's largest lender by assets which is 26%-owned by the country's HFSF bank rescue fund, aims to conclude the securitisation of the two loan portfolios between the end of 2020 and the start of 2021, three sources familiar with the matter said. JPMorgan has won the mandate for Piraeus' biggest debt auction, dubbed Project Vega, which consists of 5 billion euros ($5.62 billion) of non-performing loans (NPLs), while UBS is handling the 2 billion euro Project Phoenix sale, the sources said.
The novel coronavirus has left markets reeling and uncertain, with jobless claims in the tens of millions in the U.S. and a second wave of infections on its way. Given all this turmoil, investors may be reasonably shy about a hot new initial public offering (IPO). But the "multi-dimensional" Remark Holdings (NASDAQ:MARK) stock may be well worth considering precisely because the pandemic has caused such disruption.Source: Shutterstock Remark offers products that will help in the crisis and the company owns a stake in Sharecare, the medical startup co-founded by celebrity doctor Mehmet Oz and backed by Oprah Winfrey and Sony (NYSE:SNE).Zacks has given Remark, based in Las Vegas, a "strong-buy" recommendation. Remark's stock is set to open lower, giving smaller investors the opportunity to benefit from an IPO, which could be announced in the next few months, according to John Gilliam at Seeking Alpha.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThere are some reasons for caution, but in all, MARK looks like a very strong opportunity given the incredibly useful technology it produces. MARK Stock: Remark Scanning and Imaging Products for CompaniesRemark's innovative products include thermal imaging and scanning solutions that are already in use in Nevada. This artificial intelligence-driven tech can "scan high traffic areas to detect individuals with higher than acceptable skin temperature," the Wall Street Journal reports. * 10 Robotics Stocks on the Technological Cutting Edge Remark claims its products can be used with minimal training and scans for thermal irregularities in crowds faster than competing products by finding the "most accurate part on the face to take the temperature." The feature enables one employee to quickly check a large number of customers or workers.Moreover, the scanning device can detect compliance with PPE and social distancing rules and check clearances for certain work areas, possibly eliminating some individual security measures and reducing person-to-person contact.These devices have already seen "very strong demand," according to Remark CEO Kai-Shing Tao, who reports that the firm is "closing on average one or two a week" with companies anticipating full reopening in the coming weeks and months. Remark Products for RetailIn addition to its highly in-demand and much-needed solutions for the coronavirus, Remark has made a deal with China Mobile (NYSE:CHL) to provide all of its 17,800 stores with AI technology enabling "facial-ID, traffic counting, and smart queue management."This data will allow the company to streamline and optimize traffic flow in its stores by giving customers information about the nearest stores and number of customers in each one, and it allows them to get in line for a customer service agent before they arrive, via an online ticketing system.Such technology can significantly improve customer service, making for happier customers and a more successful brand. Additionally, by reducing foot traffic, these solutions can slow the spread of coronavirus and help companies operate smoothly with reduced physical capacity in stores. Some Reservations, But Remark Is Worth a LookRemark's health technology is entering a crowded field, with several companies producing similar products. While the company seems to have an advantage, having already put its devices successfully to use in its home market, some investors may wish to wait and see how Remark's solutions perform against competitors.Additionally, InvestorPlace notes, the company's CEO "appears to have no prior executive experience at a major technology company." Tao's previous positions were as chairman and CEO of Pacific Star Capital Management, founded in 2003, and as a partner at FALA Capital Group, a "single-family investment office." The Remark website lists no other company executives.Serving on the Remark board, however, are some high-profile names, including Theodore Botts, former executive at UBS (NYSE:UBS) and Goldman Sachs (NYSE:GS) and Dr. Elizabeth Xu, former CTO of BMO Software. Remark's celebrity endorsements and timely products may well give investors confidence, and overall, it seems like Remark Holdings stock may be a risk worth taking.As of this writing, Jody Bennett did not hold a position in any of the aforementioned securities. More From InvestorPlace * Why Everyone Is Investing in 5G All WRONG * Top Stock Picker Reveals His Next 1,000% Winner * The 1 Stock All Retirees Must Own * Look What America's Richest Family Is Investing in Now The post Remark Has the Tech to Combat Covid-19, But Is It a Buy? appeared first on InvestorPlace.
(Bloomberg) -- UBS Bank AG is no longer working on the U.S. initial public offering of the owner of Blued, China’s biggest LGBTQ dating app, after gauging the market, joining a number of other banks in curbing work on some U.S. listings by Chinese firms.The Swiss bank had been involved in the IPO until recently, people familiar with the matter said, who asked not to be identified as the information is private. However UBS’s name did not appear on BlueCity Holdings Ltd.’s filing on Tuesday with the U.S. Securities and Exchange Commission.The bank did not agree with the timing of the public filing after gauging initial investor interest, one of the people said. A spokesman for UBS declined to comment. Blued declined to comment in an emailed statement. There is no indication that the decision had anything to do with LGBTQ issues.Blued lost Credit Suisse earlier this year after the bank halted work on the IPO for unknown reasons, Bloomberg News reported. Major banks have been scaling back their work on some U.S. IPOs, particularly small ones, by Chinese firms as concerns mounted last year about investor demand and deal sizes shrank. Other companies to have lost banks working on their floats include Lizhi Inc., Canaan Inc. and EHang Holdings Ltd.The spectacular downfall of Luckin Coffee Inc, a poster child for Chinese startups, amid an accounting scandal in April added to the negative sentiment around Chinese listings in America. Rising tensions between the U.S. and China, which have extended to Chinese companies’ access to U.S. capital markets, have also cast a shadow on the flow of deals.However, the most recent U.S. IPOs by firms from the Asian nation have mostly done well. Burning Rock Biotech Ltd. has risen 48% from its offer price while crowd-sourced delivery platform Dada Nexus Ltd. is trading 5% above its IPO price. The gains stand in contrast to a string of lackluster U.S. debuts by Chinese firms last year.UPCOMING LISTINGS:JD.com Inc.Hong Kong exchangeSize $3.9bListing June 18Bank of America, UBS, CLSAChina Bohai BankHong Kong exchangeSize about $2bPre-marketing from June 22CCBI, Haitong, ABC International, CLSASK BiopharmaceuticalsKorea stock exchangeSize up to $805mPricing June 19, listing around July 2NH Investment & Securities, Citi, Morgan StanleyHygeia Healthcare Holdings Co.Hong Kong exchangeSize up to $286mPricing June 19, listing June 29Morgan Stanley, HaitongKangji Medical Holdings Ltd.Hong Kong exchangeSize up to $404mPricing June 19, trading June 29Goldman Sachs, Citic Securities, Bank of AmericaGenetron HoldingsNasdaq exchangeSize up to $176mPricing June 18, trading June 19Credit Suisse, CICCSmoore International HoldingsHong Kong exchangeSize at least $800mPre-marketing from June 15CLSAZhenro Services GroupHong Kong exchangePre-marketing from June 15CCB International, BNP ParibasShenzhen Hepalink Pharmaceutical GroupHong Kong exchangePre-marketing from June 15Goldman Sachs, Morgan StanleyMore ECM situations we are following:Far East Horizon Ltd. is seeking $300 million in convertible bonds due in 2025, according to terms of the deal obtained by Bloomberg NewsYes Bank Ltd. is planning to raise at least 80 billion rupees ($1 billion) in a public offering of shares to boost its capital, according to people familiar with the matterNoritsu Koki is offering 2.6m shares in JMDC, according to terms of the deal obtained by Bloomberg NewsChina Pacific Insurance Group Co. gained as much as 2.1% on its first day of trading on the London Stock Exchange, after raising $1.8 billion from investors in the biggest European stock offering ever from a Chinese companyInstitutional investors are bidding for JD.com’s Hong Kong shares before this week’s debut at slightly more than the listing priceLine Corp. is offering 2.093m shares in Freee KK, according to terms of the deal obtained by Bloomberg NewsSee also:Asia ECM Weekly AgendaIPO dataU.S. ECM WatchEU ECM WatchTo receive the ECM Watch in your inbox daily, click the “subscribe” button at the top of this article.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
UBS Investment Bank today announced coupon payments for 5 ETRACS Exchange Traded Notes (the "ETNs"), all traded on the NYSE Arca.
On CNBC's "Mad Money Lightning Round," Jim Cramer said he's not going to recommend Ares Capital Corporation (NASDAQ: ARCC). He doesn't know what are its investments.UBS Group AG (NYSE: UBS) doesn't have a great dividend, said Cramer. He is not a buyer of the stock. He added that Wells Fargo & Co (NYSE: WFC) has a better dividend. He is starting to warm up again to Wells Fargo because it got out of the auto loan business.Cramer believes in RNA technology and he likes Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT). He sees as a speculative stock and he wouldn't commit a lot of capital to it.Alteryx Inc (NYSE: AYX) is a buy, said Cramer.There is too much heavy lifting for Lyft Inc (NASDAQ: LYFT), with problems in cities and COVID-19, explained Cramer.See more from Benzinga * Cramer Gives His Opinion Alteryx, Johnson & Johnson And More(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
UBS analysts led by Eric Sheridan reiterated their ‘buy’ rating and $3,000 price target on shares of Amazon, on the premise that there are several factors pointing to more room for the e-commerce giant to grow. Although COVID-19 will impact the company’s margins for 2020, long-terms drivers are still intact. The Final Round panel discusses the call.
Roth IRA conversions have been on the rise. First, the coronavirus-induced market rout lowered the value of assets in traditional IRAs, diminishing the tax bill for moving them into Roths. Over the course of the long bull market that expired in mid-March, DIY investors and financial advisors alike shifted to passive investing, but the volatility of the past few months has sparked renewed interest in active strategies, even among some longtime skeptics.
A U.S. judge on Thursday said institutional investors, including BlackRock Inc <BLK.N> and Allianz SE's <ALVG.DE> Pacific Investment Management Co, can pursue much of their lawsuit accusing 15 major banks of rigging prices in the $6.6 trillion-a-day foreign exchange market. U.S. District Judge Lorna Schofield in Manhattan said the nearly 1,300 plaintiffs, including many mutual funds and exchange-traded funds, plausibly alleged that the banks conspired to rig currency benchmarks from 2003 to 2013 and profit at their expense. "This is an injury of the type the antitrust laws were intended to prevent," Schofield wrote in a 40-page decision.